HRS9531 Injection Placebo

Phase 1

FFujian Shengdi Pharmaceutical Co., Ltd.

HRS9531 Injection Placebo is one of 4 therapeutic programs targeting Overweight and Obesity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Overweight and ObesityActive, not recruiting

Overweight and ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Overweight and Obesity

#DrugCompanyPhaseTrials

ATR-258

AAtrogi AB

Phase 2

1 2

LAE102 IV

LLaekna Limited

Phase 1

1 3

HRS9531 Injection Placebo

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 1

1 4

AZD9550

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Overweight and Obesity

NCT07559136

Q3 2028

Phase 2Recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NCT07660848

Clinical

Trials by Indication[1]

Overweight or Obesity1 trial

A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Completed·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT05881837·249 enrolled

Overweight and Obesity1 trial

A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of HRS9531 Injection in Chinese Adolescents With Obesity

Active, not recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 1·NCT07559136·48 enrolled

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Master Protocol Clinical Trial to Investigate the Efficacy and Safety of HRS-4729 Injection and HRS9531 Injection in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT07660848·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HRS9531 Injection Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for HRS9531 Injection Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Fujian Shengdi Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: FFujian Shengdi Pharmaceutical Co., Ltd.

HRS9531 Injection Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Trials by Indication[1]

Overweight or Obesity1 trial

Overweight and Obesity1 trial

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

References

Drug Info

Quick Facts

Related News